Novocure Shares Surge Over 20% on Strong Q2 2026 Cancer Treatment Revenue Beat
Novocure, an Israeli biotech company specializing in cancer treatments using electric field targeting, reported second-quarter 2026 revenues of approximately $184 million, marking a 16% increase year-over-year and surpassing analyst expectations of $172 million. The company raised its full-year 2026 revenue guidance from $690-$710 million to $710-$725 million. Notably, the newer lung cancer product Optune Lua generated $5.4 million in Q2, nearly doubling its Q1 revenue, despite mixed expert opinions on market adoption. Additionally, Optune Pax for pancreatic cancer, approved for marketing in February 2026, contributed $1.6 million in Q2 revenue. Novocure anticipates combined revenues of $20-$30 million from these two new products for the full year.
The successful launches of these products are crucial as Novocure’s main market, brain cancer treatment, has shown signs of saturation, especially in the U.S., where revenues remained flat while growth came mainly from outside the U.S. The company is approaching profitability, with a Q2 net loss of $15 million (13 cents per share), better than the expected 33 cents loss, helped by an improved gross margin from 74% to 78%. Novocure held $440 million in cash at the end of the reporting period and has not been profitable since 2019 due to heavy clinical trial and marketing investments. CEO Frank Leonard, who took over at the end of 2025, emphasized his goal to lead the company to profitability.
Looking ahead, Novocure expects a U.S. FDA decision in Q4 2026 on marketing approval for its treatment targeting brain metastases from lung cancer. The company also plans to complete patient enrollment in a Phase III trial for its first-line glioblastoma brain cancer treatment, which could enable earlier-stage use and benefit more patients over longer periods.
